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Background/Aims: The aim of this study was to investigate the dose-
response effect of lactoferrin (Lf) intervention on gene expression in the
hippocampus of postnatal piglets during neurodevelopment.
Methods: Fifty-one 3-day-old piglets were randomly allocated into a high
(H) Lf dose group (n ¼ 18), a low (L) Lf dose group (n ¼ 17) and a control (C)
group (n ¼ 16). Piglets were fed sow milk replacer supplemented with Lf at
285 mg/kg/d (H), 155 mg/kg/d (L) and 16 mg/kg/day (C). Piglets were
euthanized at 38 days of age. RNA transcript proﬁling in the hippocampus
was carried out using RNA isolated from 10 piglets/gp on Porcine Affyme-
trix. A TaqMan® Gene expression assay based on qPCR was used to validate
the microarray ﬁndings. The results were analyzed using the Partek Ge-
nomics Suite 6.5 software and Ingenuity System.
Results: Low-dose Lf activated neurotrophin signalling pathways and
modulated expression of genes associated with neurodevelopment,
learning & memory, including BDNF, FGFR, IRS1 and CAMKK1. Functional
analysis showed network signalling impacted brain development, neuron
structure and long-term potentiation. In contrast, piglets on the high dose
of Lf showed no effect on neurotrophin signalling but an increase in gene
expression and signalling pathways leading to cell death/apoptosis and
decreased neurogenesis.
Conclusions: Low-dose Lf supplementation up-regulated neurotrophin
signalling pathways associated with neurodevelopment and cognition, a
ﬁnding in contrast to piglets on a high dose of Lf. The molecular mecha-
nism(s) underling this paradoxical ﬁnding remains under study.
Funding source(s): Medical School, Xiamen University & Nestle Research
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Background: Krill oil (KO) has been suggested to have higher bioavail-
ability of EPA and DHA compared with ﬁsh oil. There are limited reports on
the postprandial effects of KO. This study investigates the impacts of
supplementation with KO and ﬁsh oil (FO) on plasma lipid proﬁles in the
postprandial state.
Methods: This is a randomised cross-over study. Test meals consisting
fresh mashed-potato and 15 g of olive oil (OO) and 5 g of with three oil
supplements (KO, FO or OO) were randomly provided on each study day
with seven days wash-out period between. Blood samples were collected
at the baseline and post consumption of test meal/supplement on hourly
basis for 5 hours. Postprandial changes were assessed using SPSS. SPA-
NOVA for repeated measure was performed to assess the changes between
the treatments. One-way ANOVA and multiple comparisons using Tukey
HSD post-hoc analysis were also performed to assess the changes in the
parameters over timewithin the treatment group. P < 0.05 was considered
statistically different.
Results: There were no signiﬁcant changes in the postprandial TAG levels
in either chylomicron or plasma between the three oil treatments (p ¼
0.783). However within the treatment groups, changes in TAG with time
after oil consumption were signiﬁcantly different (p < 0.001) and the
magnitude of changes varies in each treatment.
Conclusions: Therewere no signiﬁcant difference in the absorption of TAG
in chylomicron or plasma between FO and KO. Since KO contains n-3 fatty
acids in phospholipids, n-3 proﬁle in postprandial plasma phospholipidshould be examined.
Funding source(s): College of Health and Biomedicine, Victoria University,
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WHY ARE FISH OIL SUPPLEMENTS APPARENTLY FAILING TO
REPRODUCE FISH CONSUMPTION EPIDEMIOLOGY IN RCT FOR
CARDIOVASCULAR DISEASE?
P. McLennan 1, G.E. Peoples 1, M.J. Macartney 1, S.K. Venoe 2. 1Graduate
School of Medicine, University of Wollongong, NSW, Australia; 2 Faculty of
Medicine, Aalborg University, Aalborg, Denmark
E-mail address: petermcl@uow.edu.au (P. McLennan)
Background/Aims: Regular ﬁsh consumption is associated with low car-
diovascular disease risk. However, randomised control trials (RCT) of ﬁsh
oil supplements produce variable results, recently interpreted to no longer
support beneﬁcial effects of long chain n-3 polyunsaturated fatty acids
(LCn-3PUFA) EPA and DHA in treating or preventing cardiovascular
disease.
Methods: This review considers issues key to understanding the
contradiction.
Results: 1) Most RCT report no exclusion criteria for ﬁsh eaters and fewer
analyse n-3 PUFA status. Even in RCT with exclusions overlap of tissue n-3
PUFA status remain between control and treated groups. 2) Cardiac effects
(sudden death, heart failure) derive from myocardial membrane incor-
poration of DHA. The LCn-3PUFA intake in cohort studies derives from
seafood, providing more DHA than EPA, whereas most RCT use supple-
ments rich in EPA, low in DHA. 3) Nutritional and therapeutic effects of
LCn-3PUFA derive from direct and indirect mechanisms. Effects on heart
rate, heart failure and sudden death occur at lower intakes than inﬂuence
classical coronary artery disease risk factors such as hypertriglyceridaemia.
RCT designs combining cardiac and arterial disease populations and
composite endpoints propose a common substrate and assume common
mechanisms of action.
Conclusions: Many ﬁsh oil RCT included in systematic reviews are
methodologically unsound, failing to consider background diet and mul-
tiple mechanisms of LCn-3PUFA or clinical disease Mechanisms of action
must be better understood and RCT design and analysis improved to
resolve apparent contradictory effects of LCn-3 PUFA supplements and
eating ﬁsh.
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DAILY VS. WEEKLY ADMINISTRATION OF FISH OIL: BIOAVAILABILITY
AND EFFICIENCY OF DIETARY LONG CHAIN OMEGA-3 FATTY ACIDS
S. Ghasemifard 1, A.J. Sinclair 1, P. Lewandowski 1, G.M. Turchini 2. 1 School of
Medicine, Deakin University, VIC, Australia; 2 School of Life and
Environmental Sciences, Deakin University, VIC, Australia
E-mail address: samane.ghasemifard@gmail.com (S. Ghasemifard)
Background/Aims: The recommendations on the intake of long chain
omega-3 polyunsaturated fatty acids (n-3 LC-PUFA) vary from eating oily
ﬁsh (‘once to twice/week’) to consuming speciﬁed daily amounts of EPA
and DHA (‘250e500 mg/day’). It is not known if there is a difference in
the uptake/bioavailability between these two feeding strategies. In this
study, the bioavailability of a daily dose of n-3 LC-PUFA (Constant treat-
ment) versus a large weekly dose of n-3 LC-PUFA (Spike treatment) was
assessed.
Methods: Six-week old male Sprague-Dawley rats were fed either a
Constant, a Spike or Control treatment (no n-3 LC-PUFA), for six weeks. The
whole body, tissues and collected faeces were analysed for fatty acid
content.
Results: The results showed that the major metabolic fate of the n-3 LC-
PUFA was towards catabolism (b-oxidation) accounting for over 70% of
total dietary intake, whereas deposition accounted less than 25% of total
dietary intake. It was found that signiﬁcantly more n-3 LC-PUFA were b-
oxidised when originating from the Constant treatment (84% of dose),
compared with the Spike treatment (75% of dose). Conversely, it was found
that signiﬁcantlymore n-3 LC-PUFAwere depositedwhen originating from
the Spike treatment (23% of dose), than from the Constant treatment (15%
